血红素病治疗药物市场：按药物类型、按疾病类型、按分销管道、按地区 - 规模、份额、展望、机会分析，2023-2030 年

Hemoglobinopathy Treatment Drugs Market, By Drug Type, By Disease Type, By Distribution Channel, By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

出版日期: 2023年08月01日 | 出版商:

Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2023年血红素病药物的全球市场规模预计为45亿美元，预测期内（2023-2030年）复合年增长率为8.4%。

报告范围		报告详细资料
基准年	2022	2023 年市场规模	美国：45亿美元
过去的资料	2018年至2021年	预测期间	2023-2030
预测 2023-2030 年复合年增长率：	8.40%	2030年价值预测	美国：79亿美元

治疗血红素疾病的药物包括所有血红素遗传性疾病。这些主要分为两组：地中海贫血综合症和结构性血红蛋白变异（血红蛋白异常）。 HbS、HbE 和 HbC 是主要的结构性血红蛋白变异。每个组都有许多子类型和复杂类型。血红素病的临床表现变化很大，从轻度低色素性贫血到中度血液系统疾病，再到严重的终生输血依赖性贫血并伴随多重器官受累。干细胞移植是严重地中海型贫血的首选治疗方法。支持治疗而非治疗涉及终身定期输血并结合铁螯合疗法。用于治疗镰状细胞疾病症状的药物包括止痛药、抗生素、ACE 抑制剂和羟基尿。仅在有严格指征时才进行输血。目前，90%以上的患者存活至成年。接受最佳治疗的患者预计可活 50 至 60 年。血红蛋白病是最常见的单一发炎性疾病，也是世界主要健康问题之一，世界人口中约 7% 是血红素病带因者。治疗血红蛋白疾病的药物最初分布在地中海地区以及亚洲和非洲的大部分地区。国际移民已从这些地区蔓延到世界各地。如今，血红素 (Hb) 异常在欧洲许多地区被列为地方病。

市场动态

主要市场参与者不断增加的新产品推出和併购预计将推动全球血红蛋白病药物市场的成长。例如，2022年8月8日，美国跨国製药和生技公司辉瑞公司（Pfizer Inc.）与美国医疗保健公司World Blood Therapeutics, Inc.宣布，辉瑞公司（Pfizer Inc.）宣布已与美国医疗保健公司World Blood Therapeutics, Inc.达成合作协议。收购 GBT 的正式协议。透过此交易，辉瑞将以每股68.50美元现金收购World Blood Therapeutics全部流通股，扣除收购的债务和现金后企业总价值约54亿美元。两家公司董事会一致批准了本次交易。

本研究的主要特点

本报告详细分析了全球血红蛋白病治疗药物市场，并介绍了以 2022 年为基准年的预测期（2023-2030 年）的市场规模和復合年增长率 (CAGR)。我是。
它也揭示了各个细分市场的潜在收入机会，并为该市场提供了一系列有吸引力的投资建议。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和批准、市场趋势、区域前景、主要参与者采取的竞争策略等的重要见解。
根据公司亮点、产品组合、主要亮点、绩效和策略等参数对全球血红蛋白病药物市场的主要参与者进行了分析。
本研究涵盖的主要公司包括Bristol-Myers Squibb Company、GlycoMimetics Inc.、Pfizer Inc.、Anthera Pharmaceuticals Inc.、Eli Lilly and Company、Mast Therapeutics、Daiichi Sankyo Company Ltd.、Novartis International AG 和Bluebird Bio Inc . .、HemaQuest Pharmaceuticals Inc.、Emmaus Medical Inc.、Baxter International Inc.、Prolong Pharmaceuticals、Medunik USA Inc.、Sangamo Therapeutics, Inc.、Global Blood Therapeutics、Alnylam Pharmaceuticals 和 Acceleron Pharma, Inc. 将出席。
《全球血红蛋白病药物市场》报告面向该行业的各个利益相关者，例如投资者、供应商、产品製造商、分销商、新进业者和财务分析师。
透过用于分析全球血红蛋白病药物市场的各种策略矩阵，将有助于利害关係人做出决策。

Bristol-Myers Squibb Company
GlycoMimetics Inc.
Pfizer Inc.
Anthera Pharmaceuticals Inc.
Eli Lilly and Company
Mast Therapeutics
Daiichi Sankyo Company Ltd.
Novartis International AG
Bluebird Bio Inc.
HemaQuest Pharmaceuticals Inc.
Emmaus Medical Inc.
Baxter International Inc.
Prolong Pharmaceuticals
Medunik USA Inc.
Sangamo Therapeutics, Inc.
Global Blood Therapeutics
Alnylam Pharmaceuticals
Acceleron Pharma, Inc.

第 10 章

调查方法
关于出版商

简介目录

Product Code: CMI4059

Global hemoglobinopathy treatment drugs market is estimated to be valued at US$ 4.5 billion in 2023 and is expected to exhibit a CAGR of 8.4% during the forecast period (2023-2030).

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 4.5 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	8.40%	2030 Value Projection:	US$ 7.9 Bn

Hemoglobinopathy Treatment Drugs Market - IMG1

The hemoglobinopathies encompass all genetic diseases of hemoglobin. They fall into two main groups: thalassemia syndromes and structural hemoglobin variants (abnormal hemoglobins). α and β thalassemia are the main types of thalassemia; the main structural hemoglobin variants are HbS, HbE, and HbC. There are many subtypes and combined types in each group. The highly variable clinical manifestations of the hemoglobinopathies range from mild hypochromic anemia to moderate hematological disease to severe, lifelong, transfusion-dependent anemia with multiorgan involvement. Stem-cell transplantation is the preferred treatment for severe forms of thalassemia. Supportive, rather than curative, treatment consists of periodic blood transfusions for life combined with iron chelation. Drugs to treat the symptoms of sickle-cell disease include analgesics, antibiotics, ACE inhibitors, and hydroxyurea. Blood transfusions should be given only when strictly indicated. More than 90% of patients currently survive into adulthood. Optimally treated patients have a projected life span of 50 to 60 years. With approximately 7% of the worldwide population being carriers, hemoglobinopathies are the most common monogenic diseases and one of the world's major health problems. They were originally found mainly in the Mediterranean area and large parts of Asia and Africa. International migration has spread them from those areas all over the world. In many parts of Europe today, hemoglobin (Hb) defects are classified as endemic diseases.

Market Dynamics

Increasing launches of new products and mergers and acquisitions by key market players are expected to drive the global hemoglobinopathy treatment drugs market growth. For instance, on August 8, 2022, Pfizer Inc., a U.S.-based multinational pharmaceutical and biotechnology corporation, and Global Blood Therapeutics, Inc., a U.S.-based Healthcare company, announced that the companies have entered into a definitive agreement under which Pfizer will acquire GBT. Under the terms of the transaction, Pfizer Inc will acquire all the outstanding shares of Global Blood Therapeutics, Inc. for US$ 68.50 per share in cash, for a total enterprise value of approximately US$ 5.4 billion, including debt and net of cash acquired. The Boards of Directors of both companies have unanimously approved the transaction.

Key features of the study:

This report provides an in-depth analysis of the global hemoglobinopathy treatment drugs market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global hemoglobinopathy treatment drugs market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Bristol-Myers Squibb Company, GlycoMimetics Inc., Pfizer Inc., Anthera Pharmaceuticals Inc., Eli Lilly and Company, Mast Therapeutics, Daiichi Sankyo Company Ltd., Novartis International AG, Bluebird Bio Inc., HemaQuest Pharmaceuticals Inc., Emmaus Medical Inc., Baxter International Inc., Prolong Pharmaceuticals, Medunik USA Inc., Sangamo Therapeutics, Inc., Global Blood Therapeutics, Alnylam Pharmaceuticals, and Acceleron Pharma, Inc.
Global hemoglobinopathy treatment drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hemoglobinopathy treatment drugs market

Detailed Segmentation:

Global Hemoglobinopathy Treatment Drugs Market, By Drug Type:
- Analgesics
- Antibiotics
- ACE Inhibitors
- Hydroxyurea
- Others
Global Hemoglobinopathy Treatment Drugs Market, By Disease Type:
- Thalassemia
- Sickle Cell Disease
- Other Hb Variants Diseases
Global Hemoglobinopathy Treatment Drugs Market, By Distribution Channel:
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Hemoglobinopathy Treatment Drugs Market, By Region:
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia Pacific
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
Company Profiles
- Bristol-Myers Squibb Company
- GlycoMimetics Inc.
- Pfizer Inc.
- Anthera Pharmaceuticals Inc.
- Eli Lilly and Company
- Mast Therapeutics
- Daiichi Sankyo Company Ltd.
- Novartis International AG
- Bluebird Bio Inc.
- HemaQuest Pharmaceuticals Inc.
- Emmaus Medical Inc.
- Baxter International Inc.
- Prolong Pharmaceuticals
- Medunik USA Inc.
- Sangamo Therapeutics, Inc.
- Global Blood Therapeutics, Inc.
- Alnylam Pharmaceuticals
- Acceleron Pharma, Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Disease Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Product Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4. Global Hemoglobinopathy Treatment Drugs Market- COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Hemoglobinopathy Treatment Drugs Market, By Drug Type, 2018-2030, (US$ Billion)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Analgesics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
ACE Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
Hydroxyurea
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)

6. Global Hemoglobinopathy Treatment Drugs Market, By Disease Type, 2018-2030, (US$ Billion)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Thalassemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
Sickle Cell Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
Other Hb Variants Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)

7. Global Hemoglobinopathy Treatment Drugs Market, By Distribution Channel, 2018-2030, (US$ Billion)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Hospitals Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)

8. Global Hemoglobinopathy Treatment Drugs Market, By Region, 2018-2030, (US$ Billion)

Introduction
North America
Latin America
Europe
Asia Pacific
Middle East
Africa

9. Competitive Landscape

Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
GlycoMimetics Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Anthera Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Mast Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Daiichi Sankyo Company Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Novartis International AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Bluebird Bio Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
HemaQuest Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Emmaus Medical Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Baxter International Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
Prolong Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
Medunik USA Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
Sangamo Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
Global Blood Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
Alnylam Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Acceleron Pharma, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies